ActiveNCT06271668

Clinical Decision Support to Improve System Naloxone Co-prescribing

Sponsor: University of Colorado, Denver

Trial Details

Condition	Medication Abuse, Harm Reduction, Opioid Overdose, Opioid Prescribing
Intervention	Naloxone Co-prescribing Clinical Decision Support (CDS)
Status	Active
Participants	200,000
Est. Completion	31 Oct 2025
Last Updated	14 May 2026

Primary Outcome

Percentage of a high-risk opioid analgesic prescriptions receiving a co-prescription of naloxone

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: * Patients receiving an opioid prescription at discharge from inpatient/ED or close visit in outpatient settings where the clinical decision support (CDS) is implemented Exclusion Criteria: * Patients \<12 and \>89 year of age * Cancer diagnosis * Hospice care/palliative care * Sickle cell disease diagnosis * Patients who arrived in error * Patients who were triaged to obstetrics

Trial Sites

Countries

United States

View Registry Entry

Related Analysis

Clinical Decision Support Trial Targets Naloxone Co-prescribing in High-Risk Opioid Patients — Implementation Study Results Due 2025

Large-scale US study evaluating clinical decision support alerts to increase naloxone co-prescribing with high-risk opioid prescriptions. Results from 200,000 participants expected 2025, with implications for Australian healthcare systems.

Read full article →

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service